For personal use only

18 March 2026

EVE Placement Update – Cornerstone Investor Increases Funds Raised to $1.3m

- Cornerstone investor commits additional $400,000 to EVE placement
- Total funds raised under the placement increased to approximately $1.3m
- Funding supports advancement of reformulated pharmaceutical programs targeting global markets estimated to exceed US$30 billion
- Programs focus on reformulating established medicines approaching patent expiry using EVE's proprietary delivery and solubilisation technologies
- Cornerstone investor brings pharmaceutical development and commercialisation experience
- Red Leaf Securities acted as Lead Manager and Bookrunner

EVE Health Group Limited (ASX: EVE, EVE or the **Company)** provides an update to its placement announced on 13 March 2026, advising that a cornerstone investor has committed an additional $400,000 under the placement, increasing the total funds raised to approximately $1.3 million.

The cornerstone investment is being made on the same terms as the placement previously announced by the Company.

The cornerstone investment has been made by a strategic investor with experience in pharmaceutical development, regulatory pathways and global commercialisation. The investment reflects growing external support for the Company's strategy of reformulating established pharmaceutical compounds approaching patent expiry using proprietary drug delivery and solubilisation technologies.

The placement was completed at an issue price of $0.02 per share. Investors receive two free attaching unlisted options for every one share subscribed, exercisable at $0.04 and expiring two years from issue.

Red Leaf Securities Pty Ltd acted as Lead Manager and Bookrunner to the placement.

Strategy

EVE is developing reformulated versions of established pharmaceutical compounds using proprietary drug delivery and solubilisation technologies designed to improve bioavailability, onset of action and patient convenience.

The Company is progressing a growing pipeline of reformulated drug candidates targeting significant global pharmaceutical markets including sexual health therapies and cardiovascular

For personal use only

treatments. These programs utilise established pharmaceutical active ingredients with well-known safety profiles while developing novel delivery systems and intellectual property protection.

This reformulation strategy focuses on medicines approaching patent expiry where improved delivery formats may provide differentiated products that can be commercialised through licensing or supply partnerships with pharmaceutical companies that possess established regulatory capabilities, manufacturing infrastructure and distribution networks.

The addressable global markets for the therapeutic areas currently targeted by the Company are estimated to exceed US$30 billion annually.

Ben Rohr, Chief Operating Officer of EVE Health Group, said: "We are pleased to welcome a cornerstone investor with experience in pharmaceutical development and commercialisation as part of this placement."

"The additional investment strengthens the Company's funding position and reflects growing support for EVE's strategy of developing improved delivery formats for established pharmaceutical compounds targeting large global markets."

Use of Funds

Funds raised will be used to:

- advance the development of EVE's reformulated pharmaceutical candidates targeting large therapeutic markets including sexual health and cardiovascular therapies;
- progress EVE's drug delivery and solubilisation technologies underpinning its development pipeline; and
- support intellectual property and regulatory activities.

Placement Details

Following the cornerstone investment, the total size of the placement has increased to approximately $1.3 million.

Placement securities are being issued on the same terms as the placement announced on 13 March 2026 at an issue price of $0.02 per share with two free attaching unlisted options for every one share subscribed, exercisable at $0.04 and expiring two years from issue.

Subject to shareholder approval, investors will receive unlisted options exercisable at $0.04 and expiring two years from issue. In addition, 5,000,000 options exercisable at $0.04 and expiring three years from issue will be issued to the lead manager. Director participation of up to 500,000 shares under the placement remains subject to shareholder approval.

Settlement and allotment of the placement securities are expected to occur on 20 March 2026.

Authorised for release by the Board of Directors.

Company enquiries
+61 8 6465 5500
info@evehealthgroup.com.au

About EVE Health Group

EVE Health Group (ASX: EVE) is an Australian life sciences company focused on developing and commercialising innovative pharmaceutical solutions in high-growth therapeutic areas. The company's lead assets include Dyspro®, a fast-acting cannabinoid-based pastille targeting dysmenorrhoea and endometriosis, and Libbo™, an oral dissolving film for erectile dysfunction designed to deliver rapid onset and improved patient convenience. Both products leverage EVE's proprietary formulation and delivery technologies to enhance bioavailability and clinical outcomes, representing near-term commercial opportunities in large, underserved global markets.

EVE is building a vertically integrated health platform that combines proprietary pharmaceutical products with digital education, patient engagement and prescribing pathways. Through its dedicated information platforms, ReclaimMyCycle.com (women's health) and StiffIssue.com (men's health), the Company provides condition-focused education, reduces stigma and supports earlier engagement with appropriate care. These platforms integrate with telehealth and pharmacy fulfilment networks to enable responsible, scalable access to treatment within a regulated healthcare framework.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn.

For personal use only